Supplementary Explanatory Materials for the First Quarter Financial Results for the Fiscal Year Ending March 2027 | Anicom Holdings,Inc. (8715) timely disclosure

Worth reading

73In focus

0–100. This measures how worthwhile something is to read, not how good or bad the company is.

Direction

Improvement

Direction inferred from the company’s description.

Scale

2569

¥ million (year-on-year change in ordinary profit)

Wording

Conditional

How definitive the wording is.

Contents of this document

Financial Results PresentationFirst quarter of the fiscal year ending March 202711 items taken from the company’s own explanation

Financial Results Figures (The key points of this material are explained below)

Ordinary income3,530 Millions of yen+267.5%

Net income2,433 Millions of yen+274.0%

Selling, general and administrative expenses5,146 Millions of yen

Results for the three months of the current quarterOrdinary revenues: ¥21,403 million; ordinary profit: ¥3,530 million; net income: ¥2,433 million. Policies in force: 1,411,711; new contracts: 60,125. In the synergy businesses, matching services generated sales of ¥580 million and ordinary profit of ¥46 million, the health innovation business generated sales of ¥171 million and an ordinary loss of ¥74 million, and the veterinary hospital operations business generated sales of ¥820 million and an ordinary loss of ¥191 million.

Full-year earnings forecast

Ordinary revenue

81,000 Millions of yen

Ordinary income

5,000 Millions of yen

Number of contracts held

1,470,000 Engagements

New contracts

260,000 Engagements

Retention Rate

88.6 %

Claims paid

5,155 thousand cases

E/I loss ratio

63.4 %

Expense ratio based on earned premiums

31.6 %

Combined ratio

95 %

Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。Sales progress for the veterinary hospital operations business was 22%, calculated against the full-year sales forecast of ¥3,800 million. No progress rate was disclosed for the consolidated group as a whole.

What the company explained in this material

Self-assessment against the planThe company's self-assessment against its own plan.

Investment income is progressing in line with the plan. Ordinary profit is also on track to meet the plan. The veterinary hospital operations business is progressing as planned, while sales at JARVISどうぶつ医療センターTokyo are behind the sales plan.

Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.

Earned premiums1,181 Millions of yen
Incurred claims-1,027 Millions of yen
Agency commissions-122 Millions of yen
Catastrophe loss reserves696 Millions of yen
Investment income1,890 Millions of yen
Investment Expenses-308 Millions of yen
Other Ordinary Income340 Millions of yen
Other ordinary expenses-105 Millions of yen
Selling, General and Administrative Expenses24 Millions of yen

Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.

Full-year sales for the veterinary hospital operations business are forecast at ¥3,800 million. July sales at JARVISどうぶつ医療センターTokyo are expected to be approximately ¥80 million. No numerical assumptions were disclosed for foreign exchange rates, raw material prices, interest rates, or other factors.

New initiatives

Planned launch of “7Days Food Puree,” a dog treat jointly developed with ARIAKE JAPAN Co.,Ltd.
Joint patent obtained with DENBA JAPAN株式会社 concerning “methods of keeping animals.”
Opening of “Pet Hotel JARVIS Tokyo” in Minato-ku, Tokyo.
Opening the indoor dog run at Pet Hotel JARVIS Tokyo to the general public.
Expansion of the white-label initiative with domestic life and non-life insurers to 8 companies.
Share repurchases of up to ¥1 billion.

Key KPIsA metric the company considers important as a management benchmark.

Number of contracts held1,411,711 Engagements+7.1%
New contracts60,125 Engagements-13.9%
Retention Rate88.3 %
Claims paid1,263 thousand cases+8.8%
E/I loss ratio64.5 %
Year-on-year change2.1pt
Expense ratio based on earned premiums31 %
Year-on-year change△4.5pt
Combined ratio95.5 %
Year-on-year change△2.4pt
どうぶつ健活 applications62,985 Engagements0.0%
Veterinary hospitals served7,057 Hospitals+0.9%
Inventors163 People
Number of patents30 Engagements

Unit price and quantity metricsThese figures show sales broken down by price and volume.

The number of completed transactions has remained broadly flat, while the average transaction value has increased slightly. Other volume metrics, including policies in force and new contracts, were also disclosed.

Segment results

Matching Services Business
Net Sales580
Revenue unitMillions of yen
Prior-year sales596
Ordinary income46
Profit unitMillions of yen
Year-earlier ordinary profit84
Health innovation business
Net Sales171
Revenue unitMillions of yen
Prior-year sales124
Ordinary income-74
Profit unitMillions of yen
Year-earlier ordinary profit-61
Veterinary hospital operations
Net Sales820
Revenue unitMillions of yen
Prior-year sales682
Ordinary income-191
Profit unitMillions of yen
Year-earlier ordinary profit60

Medium-term management plan targets

As part of its capital policy, the company aims to maintain ESR at an appropriate level while achieving an optimal balance among growth investment, strengthening its operating base, and shareholder returns. Numerical targets and the target year were not disclosed.

Financial targets

ESR was 217.7% at the end of the fiscal year ended March 2026. No numerical target was disclosed.

Number of employees

The materials disclose 163 inventors, but the total number of employees, changes during the period, and the hiring plan were not disclosed.

Acquisition of treasury shares

The acquisition limit is ¥1 billion, with an acquisition period from 1 June 2026 to 31 July 2026. Approximately ¥480 million had been used for purchases as of the end of June 2026, and purchases totaling approximately ¥1 billion were completed on 27 July 2026. The number of shares acquired was not disclosed.

Contents of this document
Item	Details
Document type	Financial Results Presentation
Fiscal Period Covered	First quarter of the fiscal year ending March 2027
Ordinary income	3,530 Millions of yen (YoY +267.5%)
Net income	2,433 Millions of yen (YoY +274.0%)
Selling, general and administrative expenses	5,146 Millions of yen
Results for the three months of the current quarter	Ordinary revenues: ¥21,403 million; ordinary profit: ¥3,530 million; net income: ¥2,433 million. Policies in force: 1,411,711; new contracts: 60,125. In the synergy businesses, matching services generated sales of ¥580 million and ordinary profit of ¥46 million, the health innovation business generated sales of ¥171 million and an ordinary loss of ¥74 million, and the veterinary hospital operations business generated sales of ¥820 million and an ordinary loss of ¥191 million.
Full-year earnings forecast	Ordinary revenue 81,000 Millions of yen / Ordinary income 5,000 Millions of yen / Number of contracts held 1,470,000 Engagements / New contracts 260,000 Engagements / Retention Rate 88.6 % / Claims paid 5,155 thousand cases / E/I loss ratio 63.4 % / Expense ratio based on earned premiums 31.6 % / Combined ratio 95 %
Progress against full-year forecast	Sales progress for the veterinary hospital operations business was 22%, calculated against the full-year sales forecast of ¥3,800 million. No progress rate was disclosed for the consolidated group as a whole.
Self-assessment against the plan	Investment income is progressing in line with the plan. Ordinary profit is also on track to meet the plan. The veterinary hospital operations business is progressing as planned, while sales at JARVISどうぶつ医療センターTokyo are behind the sales plan.
Segment results	Segment Matching Services Business / Net Sales 580 / Revenue unit Millions of yen / Prior-year sales 596 / Ordinary income 46 / Profit unit Millions of yen / Year-earlier ordinary profit 84, Segment Health innovation business / Net Sales 171 / Revenue unit Millions of yen / Prior-year sales 124 / Ordinary income -74 / Profit unit Millions of yen / Year-earlier ordinary profit -61, Segment Veterinary hospital operations / Net Sales 820 / Revenue unit Millions of yen / Prior-year sales 682 / Ordinary income -191 / Profit unit Millions of yen / Year-earlier ordinary profit 60
Breakdown of Factors Affecting the Change	Factors Earned premiums / Amount 1,181 Millions of yen, Factors Incurred claims / Amount -1,027 Millions of yen, Factors Agency commissions / Amount -122 Millions of yen, Factors Catastrophe loss reserves / Amount 696 Millions of yen, Factors Investment income / Amount 1,890 Millions of yen, Factors Investment Expenses / Amount -308 Millions of yen, Factors Other Ordinary Income / Amount 340 Millions of yen, Factors Other ordinary expenses / Amount -105 Millions of yen, Factors Selling, General and Administrative Expenses / Amount 24 Millions of yen
Key KPIs	1,411,711 Engagements (YoY +7.1%), 60,125 Engagements (YoY -13.9%), 88.3 %, 1,263 thousand cases (YoY +8.8%), 64.5 %, 31 %, 95.5 %, 62,985 Engagements (YoY 0.0%), 7,057 Hospitals (YoY +0.9%), 163 People, 30 Engagements
Unit price and quantity metrics	The number of completed transactions has remained broadly flat, while the average transaction value has increased slightly. Other volume metrics, including policies in force and new contracts, were also disclosed.
Number of employees	The materials disclose 163 inventors, but the total number of employees, changes during the period, and the hiring plan were not disclosed.
Assumptions Underlying the Business Outlook	Full-year sales for the veterinary hospital operations business are forecast at ¥3,800 million. July sales at JARVISどうぶつ医療センターTokyo are expected to be approximately ¥80 million. No numerical assumptions were disclosed for foreign exchange rates, raw material prices, interest rates, or other factors.
Medium-term management plan targets	As part of its capital policy, the company aims to maintain ESR at an appropriate level while achieving an optimal balance among growth investment, strengthening its operating base, and shareholder returns. Numerical targets and the target year were not disclosed.
Financial targets	ESR was 217.7% at the end of the fiscal year ended March 2026. No numerical target was disclosed.
Acquisition of treasury shares	The acquisition limit is ¥1 billion, with an acquisition period from 1 June 2026 to 31 July 2026. Approximately ¥480 million had been used for purchases as of the end of June 2026, and purchases totaling approximately ¥1 billion were completed on 27 July 2026. The number of shares acquired was not disclosed.
New initiatives	Planned launch of “7Days Food Puree,” a dog treat jointly developed with ARIAKE JAPAN Co.,Ltd., Joint patent obtained with DENBA JAPAN株式会社 concerning “methods of keeping animals.”, Opening of “Pet Hotel JARVIS Tokyo” in Minato-ku, Tokyo., Opening the indoor dog run at Pet Hotel JARVIS Tokyo to the general public., Expansion of the white-label initiative with domestic life and non-life insurers to 8 companies., Share repurchases of up to ¥1 billion.

Items this document does not state (12)

Net SalesOperating profitGross Profit MarginOperating profit marginNumber of stores and locationsRisk amount incorporated into the outlookAnnual DividendPayout ratioCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Stable acquisition of new contracts, expansion of peripheral businesses, increased investment income, and the elimination of contract transfer costs related to AXA Direct.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.